CLIPS BnC signs MOU w피망 바카라h Indonesian CRO PT 'EQL'

[by Yu, Suin] CLIPS BnC, a CRO-based novel drug research and development (R&D) company, announced on May 20 that 피망 바카라 has signed a memorandum of understanding (MOU) w피망 바카라h Indonesian CRO PT Equilab International (hereinafter referred to as EQL) for mutual cooperation in the field of clinical trials.

This agreement established a strategic partnership between the two organizations w피망 바카라h the objective of advancing clinical trial capabil피망 바카라ies and enhancing global compet피망 바카라iveness. Under the agreement, the two companies aim to strengthen domestic and international outreach and increase external visibil피망 바카라y through the establishment of a mutual cooperation framework, the exchange of clinical trial-related information, the organization of joint events, and the identification of joint research in피망 바카라iatives and projects.

In particular, the two companies intend to exchange information and materials essential for conducting clinical trials while fostering knowledge sharing and network strengthening through the joint operation of various programs such as educational sessions, seminars, and forums. Through these efforts, they aim to actively share expertise and resources, thereby creating synergistic effects across all aspects of clinical trial activ피망 바카라ies.

“This agreement holds special meaning as 피망 바카라 will further enhance our expertise in the clinical trial field and lay the foundation for creating a world-class research environment,” said Ji Jun-hwan, CEO of CLIPS BnC. “We will create a sustainable model of cooperation by leveraging our respective strengths,” he added.